INTRODUCTION
Large tumor burden is associated with suppression of the host's immune response to foreign antigens in both humans and animals (1, 2) . Defects that occur in the specific immune response include both decreased proliferation and cytolytic activity (3, 4) . Specific immunity is a consequence of T cells, through the T cell receptor (TCR), recognizing peptide fragments of foreign antigens in the context of self-major histocompatibility molecules while simultaneously receiv-ing other costimulatory signals (5) . Both major histocompatibility antigens and the costimulatory signals exist on professional antigen-presenting cells (APC). These APC include monocytic and dendritic cells. The T cell recognizes specific antigen in the context of a major histocompatibility antigen through its unique TCR. Once the TCR is engaged, signals are transduced into the cytoplasm through the CD3 complex, which is composed of six polypeptides, ye, &s, and ( dimers (6) . ( may also consist of homodimers or heterodimers with -1 or FcERIy. (, q, CD3e, and FcsRI all have the ability to transduce signals independently into the cytoplasm (7) . It is currently unclear as to the individual role of each of these polypeptides in signal transduction and T cell activation.
Suppression of T cell responses to activation signals is also not completely understood. In murine tumor models, where suppression has been documented, studies suggest that suppressor T cells, suppressor macrophages, or suppressive cytokines secreted by tumor cells induce the impaired immune response in T cells (4, (8) (9) (10) . Studies evaluating the suppressive effects of monocytic cells on T cells have suggested that either adherent macrophages (10) (11) (12) (13) or monocytes (14, 15) contribute to the decreased T cell response to activation signals and also decreased the expression of the ( chain, a major signaling protein in the TCR-CD3 complex; however, the role of soluble factors versus cellassociated gene products in mediating these effects is unclear. Studies demonstrate that while many soluble factors from monocytic cells contribute to the down-regulation of T cell responses to alloantigens (10), a contact-dependent signal is required to decrease the expression of the ( chain (15) . The effects of contact-dependent signals delivered by monocytes to T cells on allogeneic responses is unknown.
We have investigated the mechanism of T cell suppression to alloantigens in a murine model of large tumor burden. In this model, cells of the monocytic lineage, as defined by expression of CD llb/Mac-i, gradually increase in number in the spleens of the mice as tumor size increases. In this paper, we describe the effects of these monocytes obtained by negative selection on T cells from both tumor-bearing and normal mice. MATERIALS In addition to its decreased cytolytic activity, the yield of cells from the late tumor-bearing mouse spleen was reduced compared with normal mouse spleen after in vitro sensitization. This finding suggested a decreased ability of the spleen cells from late TBM to proliferate in response to allogeneic stimulation. To test this hypothesis, proliferation was measured after stimulation with irradiated allogeneic spleen cells. Under conditions that allowed significant proliferation of normal mouse lymphocytes, minimal proliferation was detected in late TBM lymphocytes (Fig. IC) . Similar effects were observed at all time points (Days 3-6) at different responderto-stimulator cell ratios (data not shown).
Spleens from Tumor-Bearing Mice Have a Higher Percentage of Monocytes, as Defined by the CD 1 lb/Mac-I Antigen, than Spleens from Normal Mice To define the cell types that mediated the change in T cell responses, spleen cell suspensions from normal and late tumor-bearing mice were analyzed by flow cytometry with antibodies to mouse CD90/Thy-1.2, CD45R/B220, and CDl lb/Mac-I (Fig. 2) . In late tumor-bearing mice, the percentage of CD90/Thy-1.2-positive spleen cells changed slightly from 31 to 27% of total cells, and the percentage of CD45R/B220-positive spleen cells decreased from 41 to 30%. In contrast, the percentage of CDL lb/Mac-I-positive spleen cells increased from 2 to 15 %. Although some subsets of cytolytic T cells express CDL lb, it is unlikely that this subset represented splenic T cells, because the population of expanded CDl lb' cells showed a larger size as measured by forward light scatter than the subsets staining with Thy-1.2 antibody. In addition, cells that expressed the Mac-I antigen also coexpressed small amounts of Mac-2 antigen, another marker of cells of monocytic lineage (data not shown). The minor shift in the T cell population suggested that the change in responsiveness of T cells was qualitative rather than quantitative. This small decrease in percentage would be unlikely to account for the large decrease in proliferation when stimulated. However, the larger shifts in the B cell and monocyte populations suggested that tumor growth was influencing their growth and survival to a greater extent in vivo. (Fig. 4A) . In contrast, depletion of CD45R/B220 cells, largely composed of B cells, resulted in a small loss of suppression and was much less effective than removal of CD1 lb/ Mac-I cells (Fig. 4A) . As expected, no proliferation was observed after CD90/Thy-1.2-positive cell depletion or with a nonspecific control antibody (Fig. 4A) . Although T cells demonstrated increased proliferation to allogeneic stimuli when the monocytes were removed, proliferation did not increase to levels of control normal mouse spleen cells.
To determine whether the T cell could act in trans on normal T cells, mixing experiments were performed with tumor-bearing spleen cells depleted or enriched for T cells (Fig. 4B) . CD90/ Thy-1.2-depleted TBM spleen cells inhibited normal mouse spleen cells at a 9:1 ratio to the same extent as TBM cells without depletions (Fig. 4B) . Enrichment of T cells by CD45R/B220 and CD1 lb/Mac-I depletion demonstrated a greater proliferative response than nondepleted cells (Fig. 4B) . Therefore, it appeared that the CDL lb/Mac-I cell from TBM was responsible for the major inhibitory signals to T cells.
Cell Contact Is Required for Inhibition of Naive Spleen Cell Responses to
Alloantigens by the CD90/Thy-1.2-, CD45R/B220 Cell Population from Tumor-Bearing Mouse Spleen To determine whether cell contact or soluble factors mediated this effect, inhibition by the CDllb/Mac-I cell was analyzed further by supernatant transfer and membrane separation experiments. Transfer of supernatant from CD90/ Thy-1.2 and CD45R/B220 depleted TBM spleen failed to confer suppression upon normal spleen cells (Fig. 5A) . Also, the addition of neutralizing antibodies to mouse transforming growth factor-13 (TGF-,), interleukin 10 (IL-10), and tumor necrosis factor a (TNFa) or indomethacin, which inhibits PGE2 production, to proliferation assays using TBM spleen did not change T cell proliferation (data not shown). In contrast, cell contact conferred this inhibition (Fig. 5A) .
To confirm these results, experiments were also performed with cells of the TBM separated from normal mouse spleen by a membrane in a proliferation assay. When the cells were separated, there was no inhibition of proliferation, but when cell contact was allowed there was significant inhibition of proliferation of the normal mouse cells (Fig. 5B) 
DISCUSSION
We have demonstrated a quantitative increase in monocytes which inhibit T cell proliferation and cytotoxicity in mice with large burdens of a subcutaneously implanted tumor, CT26. Decreased immune function was observed in animals with a large tumor burden. Cytolytic and proliferative T cell responses to alloantigen and natural killer (NK) activity were markedly diminished. Increased levels of monocytic cells were detected in the spleen of these animals, and we find that this cell type was responsible for the reduction in T cell response. Finally, we have found that contact between T cells and monocytes was required for this inhibitory effect.
This study provides insight into the mechanism of tumor-induced immunosuppression. Defects in the immune response of tumor-bearing animals have been attributed to soluble factors produced by tumor cells, which act directly on T cells or indirectly, through the induction of other suppressor cells, either T cells or macrophages (4, (8) (9) (10) . In the animal model described in this study, it was found that the monocyte conferred suppressive activity on the T cell. Other groups who have found monocytic cells to be suppressive have shown that soluble factors, including PGE2 and TGF-f3, were important in the suppression of lymphocyte proliferation (1 1-14) . In contrast, we found that cell contact was required to inhibit T cell function. These differences could be accounted for by a difference in tumor type or, alternatively, by the methods used to obtain the monocytes. Studies that have found soluble factors to be important obtained monocytic cells by separating cells on the basis of adherence, which may induce activation and enhance cytokine secretion. These effects could mask the additional inhibitory effects of cell surface molecules. In the present study, cells were derived by enrichment Fas L ing of increased FasL expression in this population suggests its potential involvement in this effect. It may also provide a useful surrogate marker for tumor-induced immunosuppression. The molecular signal from monocyte to T cell in this study is membrane or cell associated. Candidate molecules could include TGF-,B and nitric oxide, as they have been demonstrated to decrease proliferation of activated lymphocytes and can be associated with the membrane (TGF-f3) (22) or lose activity quickly after being released from the cell (nitric oxide) (23) . In some instances, TGF-j3 antibodies can reverse inhibition by monocytes, for example, in hyperimmunized mice (22) , however, neither of these molecules has been demonstrated to decrease ( expression in the TCR, and neutralizing antibodies to TGF-,B did not block the negative signal to T cells in this study (data not shown). These findings suggest that TGF-f is not involved in decreasing T cell proliferation in our system.
The CD 
